Changes in Beneficial Ownership · 4
Oric Pharmaceuticals, Inc.
ORICNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10212026_091012.xml
Filing details
- Report period
- 2026-10-20
- Issuer
- Oric Pharmaceuticals, Inc.
- Issuer CIK
- 0001796280
- Trading symbol
- ORIC
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Piscitelli Dominic
- Reporting owner CIK
- 0001695028
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-20 | M · Form 4 | 14,000 | A | 4.36 | 83,828 | D |
| Common Stock | 2026-10-20 | S · Form 4[F1] | 14,000 | D | 13.5279[F2] | 69,828 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 4.36 | 2026-10-20 | M · Form 4 | 14,000 | D | 0 | 2025-07-20 | 2032-07-19 | Common Stock | 14,000 | 64,500 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.↩ 1
- F2
- Represents the weighted average share price of an aggregate total of 14,000 shares sold in the price range of $13.50 to $13.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.↩ 1
Signature 1
- Signed
- /s/ Christian Kuhlen, attorney-in-fact
- Date
- 2026-10-21
Company context
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.